Armata Pharmaceuticals (ARMP) EBIT (2016 - 2018)
Historic EBIT for Armata Pharmaceuticals (ARMP) over the last 6 years, with Q4 2018 value amounting to -$2.8 million.
- Armata Pharmaceuticals' EBIT fell 1813.95% to -$2.8 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$10.4 million, marking a year-over-year increase of 3543.58%. This contributed to the annual value of -$42.4 million for FY2024, which is 378.09% down from last year.
- Latest data reveals that Armata Pharmaceuticals reported EBIT of -$2.8 million as of Q4 2018, which was down 1813.95% from -$2.4 million recorded in Q3 2018.
- Armata Pharmaceuticals' EBIT's 5-year high stood at -$746000.0 during Q3 2017, with a 5-year trough of -$11.9 million in Q4 2016.
- Its 5-year average for EBIT is -$3.8 million, with a median of -$2.8 million in 2018.
- In the last 5 years, Armata Pharmaceuticals' EBIT crashed by 30353.74% in 2016 and then skyrocketed by 8006.57% in 2017.
- Over the past 5 years, Armata Pharmaceuticals' EBIT (Quarter) stood at -$2.6 million in 2014, then fell by 13.21% to -$2.9 million in 2015, then plummeted by 303.54% to -$11.9 million in 2016, then surged by 80.07% to -$2.4 million in 2017, then fell by 18.14% to -$2.8 million in 2018.
- Its last three reported values are -$2.8 million in Q4 2018, -$2.4 million for Q3 2018, and -$2.8 million during Q2 2018.